DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE
The aim of this paper is to outline pharmacotherapy of the ‘third-line management of CML’ (progressive disease course after sequential TKI drugs. Current management of CML with multi-TKI failure is reviewed. TKI (bosutinib, ponatinib, dasatinib, nilotinib) and non-TKI (omacetaxine mepussecinate, IFN...
Saved in:
| Main Author: | Ibrahim C. Haznedaroglu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2015-02-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/2066 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01) -
Electrochemical sensors for anticancer drugs used in the targeted therapy of chronic myeloid leukaemia
by: Totka Dodevska
Published: (2025-07-01) -
Management of Chronic Myeloid Leukemia Patients During Pregnancy (Analysis of Literature and Practical Recommendations)
by: EYu Chelysheva, et al.
Published: (2019-03-01) -
Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01) -
Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia
by: N. A. Avxentyev, et al.
Published: (2018-08-01)